Pharmedic (PMC) will pay a total cash dividend of 30%, or VND 3,000 per share, with a final record date of November 12, 2026, an ex-dividend date of November 11, and payment on November 27, 2026. With over 9.33 million shares outstanding, the payout totals about VND 28 billion, and the company has already paid two installments this year in May (14%) and September (19.64%). In Q3 2026, net revenue rose 15% to VND 146 billion, gross profit grew 23.5% to nearly VND 66 billion, and post-tax profit rose 14% to VND 22 billion. For the first nine months, revenue reached VND 403 billion, up nearly 5%, but post-tax profit fell 9% to VND 59 billion as selling, administrative and financial costs increased. PMC closed at VND 113,700 on November 3 after a 4% drop on low liquidity of about 1,200 shares, and remains about 25% below its level at the start of the year.
Summary written by Upside AI from the original article. Read the source for full details.
Original headline: Cổ đông một doanh nghiệp trên sàn sắp nhận 3.000 đồng/cp
Keywords
dividendspharmaceuticalsearnings
Open a keyword to see other news on the same topic.
Related news
- Company with female CEO born in 2002 issues important announcement
Ben Tre Pharmaceutical JSC (Bepharco, DBT) plans to issue more than 1.53 million shares to pay its 2025 dividend at a 7% ratio, with the final record date set for 16 November 2026. Shareholders holding 100 shares will receive 7 new shares, funded by undistributed after-tax profit as of 31 December 2025. If fully issued, charter capital would rise from nearly VND 219.7 billion to about VND 235 billion. Ms Nguyen Thuy Dung stepped down as chief accountant effective 2 November 2026, replaced by Mr Nguyen Nhat Phi for a term to 31 October 2027, and Ms Dung had registered to sell 14,687 DBT shares in October 2026. Tran Ngo Minh Anh, born in 2002 and daughter of Tran Ngo Phuc Vu, chairman of Nam A Bank, was appointed CEO from 1 November 2026, replacing Nguyen Khac Hanh, who resigned. In the first half of 2026, net revenue reached nearly VND 418 billion and after-tax profit nearly VND 25 billion, with DBT shares at VND 13,100 and a market cap of about VND 288 billion.
- Is AbbVie a Buy After Its Latest Earnings Report?
AbbVie reported third-quarter revenue of $17.4 billion, up 10.3% year over year, and adjusted EPS of $3.82, beating the midpoint of its guidance by about $0.07. Excluding costs tied to acquiring experimental drugs, adjusted EPS rose about 17%, from $3.36 to $3.93. Skyrizi and Rinvoq grew 22.7% and 23.9% and together made up 48.7% of revenue, while Humira sales fell to $683 million from $993 million. The company modestly raised full-year adjusted EPS guidance to $13.95 to $13.99 and increased its quarterly dividend 5.2% to $1.82, starting in February. The author remains bullish on AbbVie's long-term prospects but says its current valuation makes the 2027 guidance, due with fourth-quarter results, especially important.
- Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
Johnson & Johnson recorded about $7 billion in charges in Q3 2026, including a proposed talc litigation resolution and expenses tied to the Firefly Bio transaction and a Sail Biomedicines collaboration, which weighed heavily on earnings. Despite this, the company raised its full-year revenue and earnings guidance, with quarterly revenue up nearly 6% while GAAP earnings per share fell about 96%. The proposed talc settlement totals $5.5 billion, with an initial $3 billion payment due in 2027 and the remainder paid in later years. The author views the settlement as a net positive that could let J&J focus on long-term growth, noting that healthcare spending tends to hold up in recessions. J&J has increased its dividend for 64 consecutive years, which the author cites as evidence of the company's resilience.
- Dược Hậu Giang (DHG) Reports Lowest Quarterly Profit in Over 15 Years
Dược Hậu Giang (DHG) reported third-quarter 2026 after-tax profit down 53% to 98.5 billion VND, its lowest quarterly level since Q1 2011, as net revenue fell 11% to over 1,023 billion VND and selling expenses rose 23%. The company said some operating costs and corporate income tax increased, including the impact of global minimum tax rules. For the first nine months, net revenue grew nearly 2% to 3,584 billion VND and pre-tax profit reached 839 billion VND, or 83.3% of the full-year pre-tax target of 1,007 billion VND. As of 30 September 2026, total assets were down about 15% from the start of the year, with short-term financial investments down by over 1,021 billion VND. Financing outflows of over 1,307 billion VND mainly reflected the cash payment of the 2025 dividend at a 100% rate.
- Should You Invest in This Dividend King on the Dip?
Johnson & Johnson (JNJ) shares fell significantly after its third-quarter results, even though the company beat expectations and slightly raised its full-year guidance. Revenue reached $25.4 billion, up 5.9%, while adjusted EPS of $2.59 fell 7.5%, a decline the company attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by Darzalex and Tremfya, but medtech revenue of $8.6 billion, up 2.5%, fell short of expectations and drove the post-earnings dip, with the cardiovascular unit hurt by safety and efficacy concerns about the Impella heart pumps. The article points to new drugs such as ICOTYDE and Imaavy as medium-term growth drivers and says the Ottava robotic surgery device could help medtech recover. The author argues investors should hold the stock for the long term, citing JNJ's 64 consecutive years of dividend increases.
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
Related markets
Latest news
- Why are many countries advising people to prepare 'survival food'?
Reports say at least 33 countries have issued guidance urging households to stockpile food, water and essentials against risks such as geopolitical tensions, extreme weather, power outages and cyberattacks. Stockpile periods vary: France and the UK cite 72 hours, Canada, Japan, Mexico and the Netherlands three days, Sweden and Norway up to one week, and Germany up to 10 days. Thailand's DDPM asked families on 2/11 to keep enough for the first 72 hours after a disaster, while the Pentagon's FORTRESS program aims to let military bases operate independently for up to 90 days, a military initiative rather than public advice. Experts note these are precautionary measures and do not signal forecasts of war or an imminent major disaster.
- Stock Market Today: Dow Slides 300 Points On Election Day; Apple, Palantir Dive On Earnings (Live Coverage)
The Dow Jones index fell 300 points on Election Day, as Apple and Palantir tumbled following their earnings reports.
- Good News Or Bad? Wall Street Lowers The Revenue Bar For Google Search
After a sharp retreat in Google's stock, Wall Street analysts have lowered growth estimates for the internet giant's search advertising business. The move reduces expectations for search ad revenue.
- Morning Minute: Tom Lee Calls the Binance Hack Bullish for Ethereum
Tom Lee, head of BitMine Immersion, called the market's reaction to the $6.3 billion Binance hack, the largest crypto theft on record, “constructive.” He cited four factors: Binance covered the loss from its own balance sheet, Tether and Circle froze the stolen stablecoins within hours, no DeFi protocol collapsed, and investigators quickly attributed the attack to North Korea. ETH fell about 4% after the hack, compared with an 8% drop on day one and 20% over the following week after the February 2025 Bybit hack. BitMine holds 6,060,506 ETH, or 4.9% of circulating supply, and is 99% of the way to its 5% cap, about 49,500 ETH short. With this large weekly corporate buyer nearly finished, the article asks what ETH demand will look like without it.
- SCB cuts daily fast-transfer limit to 20 million VND
SCB has cut the daily Napas 247 fast-transfer limit for individual customers to a maximum of 20 million VND on Mobile and Internet Banking, effective from late 30/10, to strengthen transaction security and curb fraud and account takeovers. Customers needing to transfer above that cap are directed to branches or transaction offices, while many banks apply standard online transfer limits of 200 to 400 million VND per day. This is not the first change: the limit was 100 million VND at the end of 2024 and at one point fell to just 10 million VND. The bank had entered special control in October 2022 and, after closing many branches, had only 10 transaction points nationwide by mid-October this year. Savings rates for most terms are now below 1% a year, while new 12-month and 13-month deposits pay 3.7% and 8.7% a year respectively.
- How Investors May Respond To Alphabet Stock Euro Bond Sale
Alphabet has completed several euro and US dollar bond issues, including 5.250% notes due 2045 worth €995.75 million and 4.05% notes due 2030 worth €1.249688 billion, plus floating-rate euro notes, to help fund heavy AI infrastructure and data center spending. The article says this mix spreads funding risk across currencies, maturities and investor bases, while free cash flow turned negative as AI spending ramped. In the third quarter of 2026, sales reached US$127.6b and quarterly net income fell year on year, while Google Cloud revenue more than doubled and the AI-weighted backlog stood at US$514b. For analyst price targets to line up, Alphabet would need to trade on a 26.9x P/E on projected 2029 earnings, versus 14.8x today, with profit margins modeled to fall from 49.9% to 29.4%.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.